Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A
will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of
radiolabeled EDG-5506. Part B will assess bioavailability of EDG-5506 with a single oral dose
of EDG-5506 and a single intravenous dose of radiolabeled EDG-5506.